Listen to conference. Sounds like close to deal with Mayne for EU rights to nipent. Grabbed 29% market share for Dacogen and growing double digit. MP-470 will be in clinical within 3 months MP529 to follow. The positive was the strong balance sheet to support new pipeline and the point was made that big pharma is jumping on preclinical drugs prior to any phase studies. What I like best is the current pipeline are oral drugs!!!! That could be very strong news later if trials are postive. It was mentioned Dacogen sales excellent and looks like they're holding reporting the results for 3rd quarter numbers.